
Sangamo Therapeutics, Inc. Common Stock
SGMO
SGMO: Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
moreShow SGMO Financials
Recent trades of SGMO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SGMO's directors and management
Government lobbying spending instances
-
$20,000 Jul 20, 2022 Issue: None
-
$20,000 Apr 20, 2022 Issue: None
-
$30,000 Jan 20, 2022 Issue: None
-
$30,000 Oct 20, 2021 Issue: None
-
$27,000 Jul 21, 2021 Issue: None
-
$27,000 Jun 22, 2021 Issue: Medical/Disease Research/Clinical Labs
New patents grants
-
Patent Title: Artificial nucleases comprising engineered cleavage half-domains Aug. 15, 2023
-
Patent Title: Methods and compositions for treating huntington's disease Aug. 15, 2023
-
Patent Title: Separation and quantification of empty and full viral capsid particles Aug. 15, 2023
-
Patent Title: Compositions and methods for producing recombinant aav Aug. 08, 2023
-
Patent Title: Delivery of target specific nucleases Jul. 04, 2023
-
Patent Title: Genetic modification of cytokine inducible sh2-containing protein (cish) gene May. 30, 2023
-
Patent Title: Dna-binding proteins and uses thereof May. 30, 2023
-
Patent Title: Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene May. 23, 2023
-
Patent Title: Methods and compositions for gene inactivation May. 16, 2023
-
Patent Title: Targeted integration into the ppp1r12c locus May. 16, 2023
-
Patent Title: Methods and compositions for regulation of transgene expression May. 02, 2023
-
Patent Title: Methods and compositions for treating hemophilia Apr. 25, 2023
-
Patent Title: Compositions for linking dna-binding domains and cleavage domains Mar. 21, 2023
-
Patent Title: Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder Feb. 28, 2023
-
Patent Title: Targeted disruption of t cell and/or hla receptors Nov. 29, 2022
-
Patent Title: Tau modulators and methods and compositions for delivery thereof Nov. 22, 2022
-
Patent Title: Methods and compositions for treatment of a genetic condition Nov. 08, 2022
-
Patent Title: Liver-specific constructs factor viii expression cassettes and methods of use thereof Sep. 27, 2022
-
Patent Title: Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases Sep. 13, 2022
-
Patent Title: Zinc finger protein compositions for modulation of huntingtin (htt) Aug. 23, 2022
-
Patent Title: Engineered target specific nucleases Aug. 02, 2022
-
Patent Title: Targeted disruption of the t cell receptor Jun. 07, 2022
-
Patent Title: Methods and compositions for targeted cleavage and recombination Apr. 26, 2022
-
Patent Title: Targeted disruption of the mhc cell receptor Mar. 29, 2022
-
Patent Title: Zinc finger protein compositions for modulation of huntingtin (htt) Mar. 22, 2022
-
Patent Title: T cell modifying compounds and uses thereof Feb. 01, 2022
-
Patent Title: Methods and compositions for modulating pd1 Feb. 01, 2022
-
Patent Title: Methods and compositions for the treatment of fabry disease Jan. 11, 2022
-
Patent Title: Methods and compositions for targeted single-stranded cleavage and targeted integration Oct. 19, 2021
-
Patent Title: Artifical nucleases comprising engineered cleavage half-domains Oct. 05, 2021
-
Patent Title: Htt repressors and uses thereof Sep. 21, 2021
-
Patent Title: Methods and compositions for treating huntington's disease Sep. 07, 2021
-
Patent Title: Compositions for linking dna-binding domains and cleavage domains Jun. 22, 2021
-
Patent Title: Method for the treatment of lysosomal storage diseases Jun. 22, 2021
-
Patent Title: Gene correction of scid-related genes in hematopoietic stem and progenitor cells Jun. 01, 2021
-
Patent Title: Methods and compositions for regulation of transgene expression Apr. 13, 2021
-
Patent Title: Engineered target specific nucleases Apr. 13, 2021
-
Patent Title: Methods and compositions for genome engineering Apr. 06, 2021
-
Patent Title: Modulation of liver genes Mar. 30, 2021
-
Patent Title: Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases Feb. 16, 2021
-
Patent Title: Isolated human cell with an inactivated glucocorticoid receptor gene Feb. 02, 2021
-
Patent Title: Methods and compositions for enhancing targeted transgene integration Jan. 12, 2021
-
Patent Title: Modulation of stem cells using zinc finger proteins Jan. 12, 2021
-
Patent Title: Methods and compositions for delivery of biologics Jan. 05, 2021
-
Patent Title: Methods and compositions for treating huntington's disease Dec. 08, 2020
-
Patent Title: Methods and compositions for modification of a hla locus Dec. 08, 2020
-
Patent Title: Method of inactivating the ipk1 gene in corn Nov. 10, 2020
-
Patent Title: Liver-specific constructs and methods of use thereof Nov. 10, 2020
-
Patent Title: Compositions for linking dna-binding domains and cleavage domains Nov. 03, 2020
-
Patent Title: Nuclease-mediated regulation of gene expression Oct. 20, 2020
Federal grants, loans, and purchases
Followers on SGMO's company Twitter account
Number of mentions of SGMO in WallStreetBets Daily Discussion
Recent insights relating to SGMO
Recent picks made for SGMO stock on CNBC
ETFs with the largest estimated holdings in SGMO
Flights by private jets registered to SGMO